Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: NS6, NRAS1, N-ras, neuroblastoma RAS viral (v-ras) oncogene homolog, NCMS, CMNS, ALPS4
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 50 μL | $297 | 7-10 days | 7-10 days | |
| 100 μL | $496 | 7-10 days | 7-10 days |
| Description | Anti-NRAS Antibody (8O77) is a Rabbit antibody targeting NRAS. Anti-NRAS Antibody (8O77) can be used in FCM,IP,WB. |
| Synonyms | NS6, NRAS1, N-ras, neuroblastoma RAS viral (v-ras) oncogene homolog, NCMS, CMNS, ALPS4 |
| Ig Type | IgG |
| Clone | 8O77 |
| Reactivity | Human,Mouse,Rat,zebrafish |
| Application | |
| Recommended Dose | WB: 1:1000-5000; FCM: 1:10-100 |
| Antibody Type | Monoclonal |
| Host Species | Rabbit |
| Construction | Recombinant Antibody |
| Purification | ProA affinity purified |
| Appearance | Liquid |
| Formulation | 1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide. |
| Research Background | Ras superfamily is a protein superfamily of small GTPases, which are all related, to a degree, to the Ras protein subfamily (the key human members of which are KRAS, NRAS, and HRAS). Receptor tyrosine kinases and G protein-coupled receptors activate Ras, which then stimulates the Raf-MEK-MAPK pathway. GTPase-activating proteins (GAP) normally facilitate the inactivation of Ras. However, research studies have shown that in 30% of human tumors, point mutations in Ras prevent the GAP-mediated inhibition of this pathway. The most common oncogenic Ras mutation found in tumors is Gly12 to Asp12 (G12D), which prevents Ras inactivation, possibly by increasing the overall rigidity of the protein. This antibody is predicted to react with H-Ras, N-Ras and K-Ras. |
| Conjucates | Unconjugated |
| Immunogen | Recombinant Protein |
| Uniprot ID |
| Molecular Weight | Theoretical: 18 kDa. |
| Stability & Storage | Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. |
| Transport | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.